Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Harshabad Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6295-2013; OpenAlex author ID A5039128180, A5135598887; NIH RePORTER profile ID 10876828. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
2
Collaborators
133
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 7 papers, 2 grants · 2027: 1 trial

Papers 23

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. First author DOI 10.1038/s41591-026-04734-7↗
  4. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  5. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  6. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  7. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Last author DOI 10.64898/2026.04.02.26349987↗
  8. Integrative genomic identification of therapeutic targets for pancreatic cancer. Co-author DOI 10.1016/j.celrep.2025.116191↗
  9. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  10. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  11. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  12. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  13. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  14. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  15. Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care. Co-author DOI 10.1200/op.24.00237↗
  16. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  17. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  18. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  19. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  20. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246223↗
  21. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  22. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. Co-author DOI 10.1200/jco.21.01510↗
  23. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗

Trials 1

  1. Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC Principal investigator NCT07765836↗

Grants 2

  1. Clinical Accelerator Initiative grant: Harshabad Singh AWARD lustgarten:2026-harshabad-singh-mbbs-md-clinical-accelerator-initiative-grant-ha
  2. Improving response prediction to neoadjuvant therapy in pancreatic cancer K08CA286749↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 18 shared papers, 2021–2026 · strength 2.82
  2. Brian Matthew Wolpin · 18 shared papers, 2021–2026 · strength 2.74
  3. Kimberly J. Perez · 17 shared papers, 2021–2026 · strength 2.62
  4. James M. Cleary · 15 shared papers, 2021–2026 · strength 2.23
  5. Jonathan Andrew Nowak · 12 shared papers, 2021–2026 · strength 1.84
  6. Douglas Adam Rubinson · 12 shared papers, 2021–2026 · strength 1.77
  7. Brandon M. Huffman · 10 shared papers, 2021–2026 · strength 1.58
  8. Srivatsan Raghavan · 8 shared papers, 2021–2026 · strength 1.16
  9. Joseph Douglas Mancias · 6 shared papers, 2022–2026 · strength 0.95
  10. Michael Jon Pishvaian · 5 shared papers, 2024–2026 · strength 0.93
  11. Stephanie K. Dougan · 6 shared papers, 2021–2026 · strength 0.90
  12. Rishi Surana · 6 shared papers, 2022–2026 · strength 0.89
  13. Kimmie Ng · 6 shared papers, 2022–2026 · strength 0.88
  14. Andressa Dias Costa · 6 shared papers, 2022–2026 · strength 0.87
  15. Thomas E. Clancy · 5 shared papers, 2022–2026 · strength 0.72
  16. Matthew B.B. Yurgelun · 5 shared papers, 2021–2026 · strength 0.72
  17. Geoffrey Ira Shapiro · 5 shared papers, 2021–2026 · strength 0.68
  18. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  19. Thomas Adam Abrams · 4 shared papers, 2023–2026 · strength 0.60
  20. Alan D. D’Andrea · 4 shared papers, 2021–2026 · strength 0.56
  21. Hannah L. Williams · 4 shared papers, 2022–2025 · strength 0.53
  22. ANDREA C Enzinger · 3 shared papers, 2025–2026 · strength 0.52
  23. Craig Devoe · 3 shared papers, 2025–2026 · strength 0.52
  24. Eileen Mary O'Reilly · 3 shared papers, 2025–2026 · strength 0.52
  25. Michael Lawrence Dougan · 3 shared papers, 2024–2026 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.